How do you decide on 2nd line therapy in a patient with HER2+ metastatic esophageal/gastric cancer who progresses after initial response to trastuzumab-based chemotherapy?
Are there factors that would lead you to select either ramucirumab +/- paclitaxel vs T-Dxd vs chemo?
@Afsaneh Barzi, would you consider immunotherapy f...